PRELIMINARY SCIENTIFIC PROGRAMME
MASTERCLASSES | ||||||
In collaboration with | ||||||
•
|
Translation of physiology to the clinic | |||||
- | PD drug dosing and pharmacokinetics in peritoneal dialysis: neglected but important | |||||
Jan T. Kielstein, Hannover, Germany | ||||||
- | Fluid management in PD: where is the fluid? | |||||
Jeroen Kooman, Maastricht, The Netherlands | ||||||
•
|
Basic science translated from and to PD
|
|||||
- | What can nephrologists learn from fi brosis research in PD? | |||||
Janusz Witowski, Poznan, Poland | ||||||
- | What can nephrologists learn from infl ammation and immunology research in PD? | |||||
Donald Fraser, Cardiff, United Kingdom | ||||||
- | Endothelial glycocalix: a new target of research in PD and uraemia related cardiovascular disease? | |||||
Carmen Vlahu, Amsterdam, The Netherlands | ||||||
MINI LECTURES | ||||||
Live imaging of the kidney in health and disease Andrew Hall, Zurich, Switzerland |
||||||
New players in mineral homeostasis René Bindels, Nijmegen, The Netherlands |
||||||
Angiotensin and tubular salt handling Laszlo Rosivall, Budapest, Hungary |
||||||
Renal oxygen sensing and EPO Kai-Uwe Eckardt, Erlangen, Germany |
||||||
Insights into uric acid metabolism from GWAS Anna Koettgen, Freiburg, Germany |
||||||
Genetic regulation of sodium and potassium transport through WNK kinases Xavier Jeunemaitre, Paris, France |
||||||
New insights on calcium disorders Rajesh V. Thakker, Oxford, United Kingdom |
||||||
Autosomal dominant polycystic kidney disease: new insights into treatment Imed Helal, Tunis, Tunisia |
||||||
The JAK /STAT pathway in renal diseases Jesus Egido, Madrid, Spain |
||||||
Vascular and endothelial dysfunction in pre-eclampsia Kate Bramham, London, United Kingdom |
||||||
Pulmonary-renal syndrome Charles Pusey, London, United Kingdom |
||||||
Peritoneal dialysis in the management of AKI: has it been ignored? Daniela Ponce, Botucatu, Brazil |
||||||
Oliguria as a marker of AKI Wim Van Biesen, Ghent, Belgium |
||||||
AKI as a side effect of cancer therapy Sylvie Rottey, Ghent, Belgium |
||||||
Cross-fertilization between the ERA-EDTA registry and national registries Benedicte Stengel, Villejuif, France |
||||||
Where do all these CKD Stage 3 patients disappear and do not progress to CKD 4 Mustafa Arici, Ankara, Turkey |
||||||
Diabetic nephropathy - from the registry to clinical management Ivan Rychlik, Prague, Czech Republic |
||||||
History of the laboratory diagnosis of renal disease Athanasios Diamandopoulos, Patras, Greece |
||||||
Immunization against high blood pressure - an update Tomasz Guzik, Glasgow, United Kingdom |
||||||
Does renal denervation infl uence the progression on CKD? Con Dagmara Hering, Perth, Austrialia |
||||||
Does renal denervation infl uence the progression on CKD? Pro Peter J. Blankestijn, Utrecht, The Netherlands |
||||||
Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall Anneleen Pletinck, Ghent, Belgium |
||||||
Volume - Na - impedance Adrian Covic, Iasi, Romania |
||||||
The relationship between endothelial dysfunction and cardiovascular disease in CKD Mahmut Ilker Yilmaz, Ankara, Turkey |
||||||
Sodium intake: what is right for people with CKD Johannes F.E. Mann, Munchen, Germany |
||||||
State of the art of the wearable artificial kidney Claudio Ronco, Vicenza, Italy |
||||||
Klotho is a key player in cardiovascular risk during dialysis Denis Fouque, Lyon, France |
||||||
Exercise on haemodialysis Halima Resic, Sarajevo, Bosnia and Herzegovina |
||||||
Needling strategies and management Ramon Roca-Tey, Barcelona, Spain |
||||||
The infl amed uremic phenotype - a mediator of premature aging Peter Stenvinkel, Stockholm, Sweden |
||||||
Important trials in transplantation in the last 12 months Bruno Watschinger, Vienna, Austria |
||||||
Post transplantation diabetes mellitus – novel pathogenetic factors and therapeutic recommendations Mads Hornum, Copenhagen, Denmark |
||||||
SYMPOSIA | ||||||
Special Symposia | ||||||
•
|
ERA-EDTA Registry | |||||
- |
Why do girls with end-stage renal disease wait longer for transplantation than boys? |
|||||
- | Julien Hogan, La Plaine Saint-Denis, France | |||||
- |
EURODOPPS |
|||||
- |
Fergus Caskey, Bristol, United Kingdom |
|||||
- |
Racial disparities in the access to and outcomes of paediatric RRT |
|||||
- |
Lidwien Tjaden, Amsterdam, The Netherlands |
|||||
- |
Trends in the epidemiology of renal replacement therapy |
|||||
- |
Maria Pippias, Amsterdam, The Netherlands |
|||||
- |
Stage 4 CKD - first results of the EQUAL study |
|||||
- |
Moniek Van De Luijtgaarden, Amsterdam, The Netherlands |
|||||
•
|
Young Nephrologists’ Platform (YNP) - Tomorrow’s nephrology presented by the nephrologists of tomorrow | |||||
- | Overview on past and future initiatives of the YNP | |||||
Miklos Z. Molnar, Memphis, U.S.A. | ||||||
- | Innate and adaptive immunity and the kidney: a pathfi nder tale | |||||
Kathrin Eller, Graz, Austria | ||||||
- | The nephrologist of tomorrow - towards a kidney-omic future? | |||||
Francesco Pesce, London, United Kingdom | ||||||
- | Emerging factors for predicting adverse outcomes in kidney transplantation: more pieces to the puzzle? | |||||
Maarten Naesens, Leuven, Belgium | ||||||
•
|
Late Breaking Clinical Trials | |||||
•
|
The Lancet | |||||
•
|
Hot ethical issues in modern nephrology | |||||
- | When to stop or not to stop renal replacement: do ethic rules offer guidance? | |||||
- | Ethical dilemmas in living kidney donation (psychical pressure; bribery) | |||||
- | How chronic kidney diseases differ from other chronic diseases from ethical point of view? | |||||
- | Ethics and economics of rare diseases | |||||
•
|
International Practices and Improved Dialysis Outcomes: The DOPPS Program | |||||
- | The DOPPS program continues to grow - special highlights | |||||
Ron Pisoni, Ann Arbor, U.S.A. | ||||||
- | EURODOPPS: First birthday | |||||
Kitty Jager, Amsterdam, The Netherlands | ||||||
- | CKDopps: Improving outcomes in advanced CKD and the transition to dialysis | |||||
Werner Kleophas, Düsseldorf, Germany | ||||||
- | PDOPPS as a unique opportunity for ancillary research: plans for the UK PD catheter study | |||||
Martin Wilkie, Sheffield, United Kingdo | ||||||
- | Measuring the patient experience: a useful approach to improve dialysis care? | |||||
Hugh Rayner, Birmingham, United Kingdom | ||||||
Panel Discussion | ||||||
•
|
What is new and hot in paediatric nephrology: report of ESPN Working Groups activity | |||||
- | Adults and children with renal diseases: a common working area for ESPN and ERA-EDTA | |||||
Rosanna Coppo, Turin, Italy | ||||||
- | CKD mineral and bone disorder WG | |||||
Dieter Haffner, Hannover, Germany | ||||||
- | ESPN WG CAKUT/UTI/Bladder dysfunction: news and activities | |||||
Stefanie Weber, Essen, Germany | ||||||
- | Idiopathic nephrotic syndrome WG | |||||
Georges Deschenes, Paris, France | ||||||
•
|
ASN Highlights | |||||
- | Acute Kidney Injury | |||||
Ravindra L. Mehta, San Diego, USA | ||||||
- | Hypertension | |||||
Aldo Peixoto, New Haven, USA | ||||||
- | General Nephrology/CKD | |||||
Michel Chonchol, Denver, USA | ||||||
•
|
SYSKID - Prognosis and therapy of diabetic nephropathy: one size does not fit them all | |||||
- | The epidemiology of CKD in Europe: implications for healthcare policies | |||||
Kitty J. Jager, Amsterdam, The Netherlands | ||||||
- | Clinical utility of risk scores/biomarkers to predict progression and outcome in diabetic nephropathy | |||||
Peter Rossing, Gentofte, Denmark | ||||||
- | Linking biomarkers to pathophysiology and treatment response: a systems biology approach | |||||
Bernd Mayer, Vienna, Austria | ||||||
- | Enrichment strategies in clinical trials - the road to personalized medicine in nephrology? | |||||
Dick De Zeeuw, Groningen, The Netherlands | ||||||
•
|
ERA-EDTA & CSN (Chinese Society of Nephrology) Joint Symposium | |||||
- | Diabetic nephropathy: a growing challenge in China | |||||
Chuan Ming Hao, Shanghai, China | ||||||
- | Diabetic nephropathy in Europe | |||||
Carl-Erik Mogensen, Aarhus, Denmark | ||||||
- | Management of amyloidosis in China | |||||
Xiang Hua Huang, Nanjing, China | ||||||
- | Amyloidosis in Europe | |||||
Speaker to be confirmed | ||||||
•
|
ERA-EDTA & JSN Joint Symposium | |||||
- | Past, present, future: continuous challenge against kidney disease | |||||
Seiichi Matsuo, Nagoya, Japan | ||||||
- | Development of novel drugs targeting CKD: hypoxia, oxidative stress, and epigenetic | |||||
Masaomi Nangaku, Tokyo, Japan | ||||||
- | Treatment practice in patients with CKD: results from the GCKD study | |||||
Kai-Uwe Eckardt, Erlangen, Germany | ||||||
- | CKJ - translational research | |||||
Alberto Ortiz, Madrid, Spain | ||||||
•
|
Valvular heart disease in renal failure patients - Joint symposium ERA-EDTA & ESC |
|||||
- | Natural history of aortic stenosis in renal insufficiency patients | |||||
Raphael Rosenhek, Vienna, Austria | ||||||
- | TAVI procedure in renal insufficiency patients | |||||
Speaker to be confirmed | ||||||
- | Valvular calcification in CKD patients | |||||
Antonio Bellasi, Como, Italy | ||||||
- | The problem of anticoagulation in CKD patients with valvular disease | |||||
Jürgen Floege, Aachen, Germany | ||||||
•
|
NDT Pearls and Polar Views | |||||
- | Clinical science pearls in Nephrology Dialysis and Transplantation in 2013-2014 | |||||
Carmine Zoccali, Reggio Calabria, Italy | ||||||
NDT Polar Views |
||||||
ABPM for the diagnosis and the monitoring of hypertension in dialysis patients |
||||||
- | ABPM should be systematically applied in dialysis patients | |||||
Rajiv Agarwal, Indianapolis, USA |
||||||
- | ABPM should be applied only when really needed to make diagnostic or therapeutic decisions | |||||
Alan Jardine, Glasgow, UK |
||||||
•
|
ERA EDTA & ESH (European Society of Hypertension) Joint Symposium | |||||
- |
Multidisciplinary approach of adherence in hypertensive renal patients |
|||||
Michel Burnier, Lausanne, Switzerland |
||||||
- |
Ambulatory blood pressure monitoring – the neglected child in nephrology |
|||||
Josep Redon, Valencia, Spain |
||||||
- |
Bioimpedance-derived volume assessment for all hypertensives |
|||||
David Goldsmith, London, United Kingdom |
||||||
- |
Aldosterone blockade vs. dual renin-angiotensin blockade in patients with resistant hypertension |
|||||
Speaker to be confirmed |
||||||
•
|
ISN Session: addressing the global unmet needs for AKI | |||||
- | Introduction: ISN AKI 0by25: a human rights case for nephrologists | |||||
Giuseppe Remuzzi, Bergamo, Italy |
||||||
- | The burden of AKI throughout the world: existing data | |||||
Norbert Lameire, Ghent, Belgium |
||||||
- | The Global Snapshot: results of a groundbreaking study on AKI | |||||
Ravindra L. Mehta, San Diego, USA |
||||||
- | Strategies to avoid preventable deaths from AKI in low/middle income countries | |||||
Andrew Lewington, Leeds, UK |
||||||
Track 1 | ||||||
Fluid and electrolytes, tubular transport, physiology | ||||||
•
|
Acid-base regulation and the kidney | |||||
- | Alkali therapy to slow down progression of CKD | |||||
Thomas H. Hostetter, Cleveland, U.S.A. | ||||||
- | New insights into acid-base regulation and the kidney | |||||
Dominique Eladari, Paris, France | ||||||
- | Pathophysiology and clinical diagnosis of distal renal tubular acidosis | |||||
Robert Unwin, London, United Kingdom | ||||||
- | The genetics of acid-base disorders | |||||
Fiona Karet, Cambridge, United Kingdom | ||||||
•
|
New insights into phosphate handling by kidney, bone and vasculature | |||||
- | Renal handling of phosphate | |||||
Carsten Wagner, Zurich, Switzerland | ||||||
- | FGF23 regulation in bone and kidney | |||||
Klaus Olgaard, Copenhagen, Denmark | ||||||
- | Bone and vasculature crosstalk in health and disease | |||||
Gérard London, Fleury-Merogis, France | ||||||
- | The role of FGF23 and Klotho in CKD | |||||
Justine Bacchetta, Bron, France | ||||||
•
|
Channels and transporters: new drug targets | |||||
- | Inhibition of SGLT glucose transporters | |||||
Volker Vallon, San Diego, U.S.A. | ||||||
- | Calcium-sensing and regulation of tubular transport | |||||
Pascal Houillier, Paris, France | ||||||
- | Targeting the vasopressin-aquaporin axis | |||||
Peter Deen, Nijmegen, The Netherlands | ||||||
- | Targeting the water channel AQP1 | |||||
Olivier Devuyst, Zurich, Switzerland | ||||||
•
|
Mechanisms and effects of renal remodelling and ageing | |||||
- | Glomerular epithelial cells in ageing and disease | |||||
Marcus J. Moeller, Aachen, Germany | ||||||
- | Ion transport and epithelial remodelling in the renal distal tubule | |||||
Johannes Loffing, Zurich, Switzerland | ||||||
- | The renin-angiotensin-aldosterone system and the ageing kidney | |||||
Ariela Benigni, Bergamo, Italy | ||||||
- | Epithelial-mesenchymal transition (EMT) in kidney fi brosis: fact or fantasy? | |||||
Alberto Ortiz, Madrid, Spain | ||||||
Track 2 | ||||||
Hereditary disorders, development, pregnancy, paediatric nephrology | ||||||
|
||||||
- | Overview of renal storage disorders | |||||
Luca Rampoldi, Milan, Italy | ||||||
- | Cystinosis | |||||
William Van’t Hoff, London, United Kingdom |
||||||
- | New insights into lysosomal storage disorders | |||||
Carmine Settembre, Naples, Italy | ||||||
- | Renal Fanconi syndromes | |||||
Robert Kleta, London, United Kingdom | ||||||
•
|
ADPKD | |||||
- | ADPKD: emerging mechanisms in disease pathogenesis | |||||
Albert Ong, Sheffield, United Kingdom | ||||||
- | ADPKD: clinical studies in China | |||||
Chang Lin Mei, Shanghai, P.R. China | ||||||
- | ADPKD: the HALT studies | |||||
Arlene B. Chapman, Atlanta, U.S.A. | ||||||
- | Genetic testing in ADPKD: assessing clinical utility | |||||
Richard N. Sandford, Cambridge, United Kingdom | ||||||
•
|
From kidney development to kidney regeneration: deciphering developmental cues to engineer kidneys | |||||
- | From human pluripotent stem cells to early nephron | |||||
Kenji Osafune, Kyoto, Japan | ||||||
- | From pluripotent stem cells to early collecting system | |||||
Juan Carlos Izpisua Belmonte, La Jolla, U.S.A. | ||||||
- | Utilization of human nephron stem cells to repair broken kidneys | |||||
Benjamin Dekel, Ramat Gan, Israel | ||||||
- | Renal progenitor cells: a strategy for kidney regeneration | |||||
Paola Romagnani, Florence, Italy | ||||||
•
|
Growth in pediatric kidney disease | |||||
- | Clinical and epidemiological aspects | |||||
George S. Reusz, Budapest, Hungary | ||||||
- | Growth as the best clinical endpoint to assess CKD-MBD in children? | |||||
Justine Bacchetta, Bron, France | ||||||
- | Bone and growth biomarkers in 2015 | |||||
Dieter Haffner, Hannover, Germany | ||||||
- | Growth hormone therapy after two decades of practice | |||||
Lesley Rees, London, United Kingdom | ||||||
|
||||||
- | The role of complement in endothelial activation | |||||
Anna Richards, Stevenage, United Kingdom | ||||||
- | Atypical HUS genetics and treatment | |||||
Tim Goodship, Newcastle Upon Tyne, United Kingdom | ||||||
- | The glomerular response to shigatoxin in the pathogenesis of D+ HUS | |||||
Moin Saleem, Bristol, United Kingdom | ||||||
- | From mutations in complement genes to clinical use of eculizumab | |||||
Véronique Frémeaux-Bacchi, Paris, France | ||||||
Track 3 | ||||||
Glomerular diseases and general clinical nephrology | ||||||
|
||||||
- | B-cell targeting in ANCA-associated vasculitis | |||||
David Jayne, Cambridge, United Kingdom | ||||||
- | B cell targeteting in lupus nephritis | |||||
Liz Lightstone, London, United Kingdom | ||||||
- | B cell targeting in membranous nephropathy | |||||
Piero Ruggenenti, Bergamo, Italy | ||||||
- | B cell targeting in minimal change disease and FSGS | |||||
Annette Bruchfeld, Stockholm, Sweden | ||||||
•
|
IgA nephropathy | |||||
- | Genetics studies of IgAN reveal links to mucosal pathogens | |||||
Ali G. Gharavi, New York, U.S.A. | ||||||
- | Modifiable and unmodifiable risk factors for progression of IgA nephropathy | |||||
Rosanna Coppo, Turin, Italy | ||||||
- | The role of micro-RNA in IgA nephropathy | |||||
Francesco Paolo Schena, Bari, Italy | ||||||
- | Formation of IgA deposits in Berger’s disease: what we learned from animal models | |||||
Renato Monteiro, Paris, France | ||||||
•
|
Everyday questions from the glomerulonephritis clinic | |||||
- | Managing thrombotic risk in nephrotic syndrome | |||||
Vladimir Tesar, Prague, Czech Republic | ||||||
- | Approach to the patient with HIV infection referred with proteinuria | |||||
Jeremy Levy, London, United Kingdom | ||||||
- | Which patients with IgA nephropathy benefit from immunotherapy? | |||||
Jürgen Floege, Aachen, Germany | ||||||
- | Which patients with diabetes and proteinuria need renal biopsy? | |||||
Loreto Gesualdo, Altamura, Italy | ||||||
•
|
Novel therapeutic approaches in glomerular diseases | |||||
- | Biomarker-guided personalized treatment of proteinuria | |||||
Peter Mundel, Boston, U.S.A. | ||||||
- | Complement targeted therapies in glomerular diseases | |||||
Giuseppe Remuzzi, Bergamo, Italy | ||||||
- | Current management of lupus nephritis | |||||
Frédéric A. Houssiau, Brussels, Belgium | ||||||
- | IL-17 as a therapeutic target in crescentic glomerulonephritis | |||||
Ulf Panzer, Hamburg, Germany | ||||||
•
|
New aspects of podocyte diseases/podocyte stress | |||||
- | The challenge and response of podocytes to glomerular hypertension | |||||
Nicole Endlich, Greifswald, Germany | ||||||
- | The role of mechanical forces in podocyte injury | |||||
Wilhelm Kriz, Mannheim, Germany | ||||||
- | Ischemic injury of podocyte as a cause of collapsing glomerulopathy | |||||
Surya V. Seshan, New York, U.S.A. | ||||||
- | Molecular and genetic basis of inherited nephrotic syndrome | |||||
Maddalena Gigante, Foggia, Italy | ||||||
Track 4 | ||||||
Acute kidney injury and intensive care nephrology | ||||||
|
||||||
- | The health economic burden of AKI | |||||
Donal O’Donoghue, Salford, United Kingdom | ||||||
- | AKI detection and early intervention: the role of e-alerts | |||||
Mark Devonald, Nottingham, United Kingdom | ||||||
- | AKI: a true risk or predictor of CKD? | |||||
Paul Stevens, Canterbury, United Kingdom | ||||||
- | Novel treatments in AKI | |||||
Andrew Lewington, Leeds, United Kingdom | ||||||
•
|
How to avoid / treat AKI: What do we know? What do we hope? | |||||
- | Prevention of AKI, which fluid? | |||||
Donal Reddan, Galway, Ireland | ||||||
- | Are there differences in the prevention of AKI between younger and older individuals? | |||||
Norbert H. Lameire, Landegem, Belgium | ||||||
- | Mechanisms of repair after acute kidney injury | |||||
Joseph V. Bonventre, Boston, U.S.A. | ||||||
•
|
Biomarkers | |||||
- | Uremic toxin profile in AKI versus CKD: any therapeutic implications? | |||||
Raymond Vanholder, Ghent, Belgium | ||||||
- | NGAL vs KIM-1 vs other biomarkers | |||||
Orfeas Liangos, Coburg, Germany | ||||||
- | The use of biomarkers in septic AKI | |||||
Jill Vanmassenhove, Ghent, Belgium | ||||||
•
|
RRT and AKI | |||||
- | Intermittent haemodialysis and isolated ultrafiltration | |||||
Christophe Vinsonneau, Melun, France | ||||||
- | Renal replacement therapy in the emerging world | |||||
Valerie A. Luyckx, Zurich, Switzerland | ||||||
- | Individualing hemodialysate in various types of AKI | |||||
Francesco Locatelli, Lecco, Italy | ||||||
- | Should indications be uniform to start RRT in all types of AKI? | |||||
Mehmet Sukru Sever, Istanbul, Turkey | ||||||
|
||||||
Track 5
|
||||||
CKD - epidemiology, prevention, progression, pathophysiology, aging
|
||||||
|
||||||
•
|
Patient satisfaction | |||||
- | Patient satisfaction: why and how measure it in dialysis patient? | |||||
Serge Briançon, Nancy, France | ||||||
- | An overview of instruments to measure satisfaction with care in patients on renal replacement therapy | |||||
Sabine Van Der Veer, Manchester, United Kingdom | ||||||
- | How to implement patient satisfaction in practice patterns evaluation? | |||||
Luc Frimat, Nancy, France | ||||||
- | Is patient satisfaction a concept that is acceptable in a developing country? | |||||
Fayçal Jarraya, Sfax, Tunisia | ||||||
•
|
Aging kidney | |||||
- | Is there a link between foetal programming and the aging kidney? | |||||
Kerstin Amann, Erlangen, Germany | ||||||
- | Estimating GFR in the elderly in 2014 | |||||
Christophe Mariat, Saint-Etienne, France | ||||||
- | Age and association of kidney measures with mortality and end-stage kidney disease | |||||
Stein I. Hallan, San Diego, U.S.A. | ||||||
- | Impact of socioeconomic conditions on elderly CKD | |||||
Andrzej Wiecek, Katowice, Poland | ||||||
•
|
Proteinuria: therapies beyond renin-angiotensin inhibition | |||||
- | Endothelin Receptor Antagonists to lower proteinuria: looking beyond RAAS intervention | |||||
Hiddo J Lambers Heerspink, Groningen, The Netherlands | ||||||
- | Can we heal the actin cytoskeleton? | |||||
Mario Schiffer, Hannover, Germany | ||||||
- | T-type calcium channel inhibitors and proteinuria: a potential renal therapy | |||||
Bruce Hendry, London, United Kingdom | ||||||
- | Insulin and podocytes | |||||
Richard Coward, Bristol, United Kingdom | ||||||
•
|
Uremic toxicities | |||||
- | Uremic toxins and cardiovascular outcomes | |||||
Roberto Pecoits-Filho, Curitiba, Brazil | ||||||
- | Uremic toxins and renal outcomes | |||||
Griet Glorieux, Ghent, Belgium | ||||||
- | Uremic toxins and neurological outcomes | |||||
Jean-Marc Chillon, Amiens, France | ||||||
- | Uremic toxins and gut | |||||
Pieter Evenepoel, Leuven, Belgium | ||||||
Track 6 | ||||||
Hypertension, diabetes, vascular disease | ||||||
•
|
Diabetes, blood pressure and kidney disease | |||||
- | Emerging molecular footprints of diabetic kidney injury | |||||
Tobias Huber, Freiburg, Germany | ||||||
- | Divergent pathophysiology/clinical course of nephropathy in type 1 and type 2 diabetes | |||||
Paola Fioretto, Padua, Italy | ||||||
- | Albuminuria in diabetic patients: prognosis and management | |||||
Michel Jadoul, Brussels, Belgium | ||||||
- | New treatment options to retard progression in CKD patients with diabetes | |||||
Luigi Gnudi, London, United Kingdom | ||||||
•
|
Lipoproteins in CKD revisited | |||||
- | Dyslipidaemia in CKD: a risk factor for CV disease and CKD progression? | |||||
David Wheeler, London, United Kingdom | ||||||
- | Current guidelines and treatment strategies for dyslipidemia in CKD | |||||
Christoph Wanner, Würzburg, Germany | ||||||
- | Modifi cations of HDL in chronic kidney disease and their clinical relevance | |||||
Marcus Saemann, Vienna, Austria | ||||||
- | Lipoproteins, immune system and vascular disease in CKD | |||||
Thimoteus Speer, Homburg/Saar, Germany | ||||||
•
|
Renovascular hypertension – when and whom to offer revascularisation? | |||||
- | Current diagnostic algorithms in patients with renal artery stenosis | |||||
Andrzej Januszewicz, Warsaw, Poland | ||||||
- | Life after ASTRAL and CORAL: where do we go now with renal revascularization for atherosclerotic renal artery stenosis? | |||||
Philip A. Kalra, Salford, United Kingdom | ||||||
- | Fibromuscular dysplasia - current epidemiology and treatment | |||||
Pierre-Franςois Plouin, Paris, France | ||||||
- | Cardiovascular complications in patients with renovascular hypertension | |||||
Roland E. Schmieder, Erlangen, Germany | ||||||
•
|
Obesity and the kidney | |||||
- | ORG (Obesity Related Glomerulopathy) - does it exist? | |||||
Esteban Porrini, La Laguna, Spain | ||||||
- | State of the art in weight management | |||||
Hermann Toplak, Graz, Austria | ||||||
- | Obesity-associated arterial hypertension | |||||
Jens Jordan, Hanover, Germany | ||||||
- | Renoprotection in obese patient | |||||
Francesca Mallamaci, Reggio Calabria, Italy | ||||||
•
|
Vitamin D deficiency in CKD patients | |||||
- | Epidemiology of hypovitaminosis D in CKD patients | |||||
Michal Nowicki, Lodz, Poland | ||||||
- | Hypovitaminosis D and cardiovascular disease in CKD | |||||
Markus Ketteler, Coburg, Germany | ||||||
- | Vitamin D, FGF 23 and Klotho - an important triangle in CKD patients | |||||
Danilo Fliser, Homburg/Saar, Germany | ||||||
- | Treatment with vitamin D – to whom, what and when? | |||||
David Goldsmith, London, United Kingdom | ||||||
Track 7 | ||||||
End stage renal disease, dialysis, peritoneal dialysis | ||||||
•
|
CKD-MBD: update 2015 | |||||
- | New biomarkers in CKD-MBD | |||||
Marc Vervloet, Amsterdam, The Netherlands | ||||||
- | The calcium-phosphate product and FGF23 | |||||
Pablo Antonio Ureña Torres, Saint-Ouen, France | ||||||
- | Phosphate binders: which next? | |||||
Tilman Drueke, Amiens, France | ||||||
- | Which Vitamin D in dialysis patients? | |||||
Mario Cozzolino, Milan, Italy | ||||||
•
|
Vascular calcification: what’s new? | |||||
- | Mechanisms of vascular calcification in CKD-evidence for premature ageing? | |||||
Ziad Massy, Paris, France | ||||||
- | The vitamin D system and the vasculature | |||||
Sandro Mazzaferro, Rome, Italy | ||||||
- | Should we check for VC in all CKD patients? | |||||
Jordi Bover, Barcelona, Spain | ||||||
- | Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease | |||||
Vincent Brandenburg, Aachen, Germany | ||||||
•
|
Hypercoagulability in ESRD: Myth or reality? | |||||
- | Underlying causes | |||||
Jolanta Malyszko, Bialystok, Poland | ||||||
- | Risk groups and anticoagulation | |||||
Jens Lutz, Mainz, Germany | ||||||
- | Pulmonary embolism in chronic kidney disease: a lethal but overlooked disease | |||||
Gürbey Ocak, Utrecht, The Netherlands | ||||||
- | Vascular access in patients with hypercoagulability | |||||
Andrew Davenport, London, United Kingdom | ||||||
•
|
Inflammation in CKD and dialysis patients | |||||
- | Monitoring infl ammation in patients on dialysis: why, how, and what else? | |||||
Christian Combe, Bordeaux, France | ||||||
- | Uremic toxins, infl ammation and perturbation of glucose metabolism | |||||
Laetitia Koppe, Montreal, Canada | ||||||
- | Any relationship between systemic and peritoneal inflammation? | |||||
Sylvie Opatrná, Pilsen, Czech Republic | ||||||
- | Is EMT of the mesothelium related to an inherent or acquired fast peritoneal transport status and ultrafiltration failure? | |||||
Rafael Selgas, Madrid, Spain | ||||||
•
|
Dialysis in the elderly | |||||
- | End-of-life and palliative care in the dialysis setting | |||||
Ken Farrington, Stevenage, United Kingdom | ||||||
- | Assessing functional status | |||||
Eva Topinkova, Prague, Czech Republic | ||||||
- | Nutritional characteristics in the elderly dialysis patients | |||||
Daniel Teta, Lausanne, Switzerland | ||||||
- | The best peritoneal dialysis program for elderly patients | |||||
Olof Heimbürger, Stockholm, Sweden | ||||||
•
|
New osmotic agents | |||||
- | Carnitine | |||||
Mario Bonomini, Chieti, Italy | ||||||
- | GLAD | |||||
Raymond T. Krediet, Amsterdam, The Netherlands | ||||||
- | Hyperbranched polyglycerol | |||||
Asher Mendelson, London, Canada | ||||||
- | Glucose polymers | |||||
John Leypoldt, Deerfield, U.S.A. | ||||||
•
|
Personalised care and dialysis | |||||
- | Extended-hours hemodialysis: benefits and barriers | |||||
Charles Chazot, Sainte Foy Les Lyon, France | ||||||
- | Is thrice weekly dialysis adequate for all ESRD patients? | |||||
Ercan Ok, Izmir, Turkey | ||||||
- | Conservative treatment | |||||
Fergus Caskey, Bristol, United Kingdom | ||||||
- | Management of advanced CKD in the elderly | |||||
Steven J. Rosansky, Columbia, U.S.A. | ||||||
Track 8 | ||||||
Transplantation | ||||||
•
|
HLA and non-HLA Antibodies - Avoid them or treat them? | |||||
- | Non-HLA Antibodies - ready to enter the clinic arena? | |||||
Magali Giral, Nantes, France | ||||||
- | What is the best HLA-desensitisation protocol with regard to long term outcomes? | |||||
Ondrej Viklicky, Prague, Czech Republic | ||||||
- | Post-transplant DSA – ignore, follow, treat? | |||||
Thomas Fehr, Zurich, Switzerland | ||||||
- | Kidney exchange and domino-paired transplantation | |||||
Willem Weimar, Rotterdam, The Netherlands | ||||||
•
|
Viruses: transplantation in the light of new treatment options | |||||
- | Management of kidney transplant patient with chronic hepatitis C infection | |||||
Petar Kes, Zagreb, Croatia | ||||||
- | HBV and kidney transplant patients | |||||
Fabrizio Fabrizi, Milan, Italy | ||||||
- | Treatment of HEV infection after transplantation | |||||
Nassim Kamar, Toulouse, France | ||||||
- | Update on vaccines for transplant candidates and recipients | |||||
Martina Sester, Homburg/Saar, Germany | ||||||
•
|
Age dependent problems in transplantation | |||||
- | Organ age and immune responses | |||||
Marian Klinger, Wroclaw, Poland | ||||||
- | Transplantation in old recipients: what are the challenges? | |||||
Julio Pascual, Barcelona, Spain | ||||||
- | Psycho-social problems and adherence in adolescent kidney transplant recipients | |||||
Istvan Mucsi, Toronto, Canada | ||||||
•
|
Disease recurrence – are there new treatment strategies on the horizon? | |||||
- | Recurrence of atypical HUS, TMA post renal transplantation | |||||
Moglie Donnette-Le Quintrec, Paris, France | ||||||
- | Recurrent Focal Glomerulosclerosis | |||||
Paolo Cravedi, New York, U.S.A. | ||||||
- | Kidney transplantation in primary hyperoxaluria type 1 | |||||
Pierre Cochat, Bron, France | ||||||
CME COURSES | ||||||
Thursday, 28 May - 09:00-12:15 CME 1 – EURECA-m Working Group Hypertension, leukocytes and vascular disease CKD-MBD, adipokines and vascular disease Thursday, 28 May - 09:00-12:15 CME 2 - CKD-MBD Working Group Introduction First session Second session Third session Thursday, 28 May - 09:00-12:15 CME 3 – DESCARTES Working Group - In collaboration with EKITA (*) (*) EKITA is a Section of ESOT Tolerance, minimization, and living donation in 2015 The race between tolerance and minimization strategies Hurdles of living-donor kidney transplantation Thursday, 28 May - 09:00-12:15 CME 4 – Immunonephrology Working Group Autoantibodies for diagnosis and prognosis of glomerular diseases Clinical endpoints for clinical trials: toward a position paper Thursday, 28 May - 09:00-12:15 CME 5 - EUDIAL Working Group The rationale for high volume haemodiafiltration Providing high volume haemodiafiltration in clinical practice Thursday, 28 May - 09:00-12:15 CME 6 - DIABESITY Working Group Connection between obesity, type 2 diabetes and renal disease Thursday, 28 May - 09:00-12:15 CME 7 – EUTox Working group Part I Part II Thursday, 28 May - 09:00-12:15 CME 8 – Working Group on Inherited Kidney Disorders Genetic diseases of tubular potassium transport Thursday, 28 May - 13:15-15:15 CME 9 - EuroPD Working Group Physiology and pathophysiology of peritoneal membrane transport Thursday, 28 May - 13:15-15:15 CME 10 Diagnostic approach to the CKD patient with joint pain Thursday, 28 May - 13:15-15:15 CME 11 Asking the right questions: the guideline on the frail and elderly example Thursday, 28 May - 13:15-16:15 CME 12 First part Second part Thursday, 28 May - 13:15-15:15 CME 13 – European Renal Nutrition (ERN) Working Group Nutritional disorders: also after kidney transplantation Thursday, 28 May - 13:15-15:15 CME 14 Thursday, 28 May - 13:15-15:15 CME 15 Thursday, 28 May - 15:30-17:30 CME 16 - EuroPD Working Group Management of diabetics on PD Thursday, 28 May - 15:30-17:30 CME 17 Thursday, 28 May - 15:30-17:30 CME 18 Thursday, 28 May - 15:30-17:30 CME 19 Thursday, 28 May - 15:30-17:30 CME 20 Epigenetics in kidney disease |
||||||
SATELLITE MEETINGS | ||||||
return to top |